Pedersen, Eva Sophie LundeEva Sophie LundePedersen0000-0003-0293-9954Schreck, Leonie DariaLeonie DariaSchreckGoutaki, MyroforaMyroforaGoutakiBellu, SaraSaraBelluCopeland, FionaFionaCopelandLucas, Jane SJane SLucasZwahlen, MarcelMarcelZwahlen0000-0002-6772-6346Kühni, ClaudiaClaudiaKühni2024-10-252024-10-252023-08-17https://boris-portal.unibe.ch/handle/20.500.12422/169737Objectives: There is little data on SARS-CoV-2 in people with rare chronic diseases. We studied incidence and severity of SARS-CoV-2 and its risk factors in people with primary ciliary dyskinesia (PCD) from May 2020 to May 2022. Methods: We used self-reported questionnaire data from the COVID-PCD study at baseline or during weekly follow-ups. We studied factors associated with SARS-CoV-2 and symptoms using Poisson regression. Results: By May 2022, 728 people participated (40% male, median age 27 years; range 0-85). 87 (12%) reported SARS-CoV-2 at baseline or during follow-up and 62 people reported an incident SARS-CoV-2 infection during 716 person-years (incidence rate 9 per 100 person years). The strongest predictors for reporting SARS-CoV-2 were exposure during periods where Delta variant was dominant (IRR 4.52, 95% CI 1.92-10.6) and Omicron variants (IRR 13.3, 95% CI 5.2-33.8). Severity was mild; 12 (14%) were asymptomatic and 75 (86%) had symptoms among whom four were hospitalized. None needed intensive care and nobody died. Conclusion: The COVID-PCD study participants did not have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.enchronic lung disease incidence longitudinal pandemic rare disease300 - Social sciences, sociology & anthropology::360 - Social problems & social services600 - Technology::610 - Medicine & healtharticle10.48350/1860163766337210.3389/ijph.2023.1605561